Great article Snouty
keeping in mind the imuno drugs discussed in that article are T cell drugs and theirfore monoclonal antibodies, it is those very same market spaces that Imugenes "disruptive" B Cell polyclonal antibodies will obtain, with an expected greater and longer lasting response and with greatly reduced auto-immune side effects.
fp
- Forums
- ASX - By Stock
- IMU
- 2.85 billion shares on issue
IMU
imugene limited
Add to My Watchlist
0.00%
!
13.5¢
2.85 billion shares on issue, page-14
-
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
